Голимумаб в лечении псориатического артрита: эффективность и безопасность
https://doi.org/10.14412/1996-7012-2015-3-48-53
Аннотация
Фактор некроза опухоли a (ФНОa) занимает центральное место в патогенезе аутоиммунных воспалительных заболеваний опорно-двигательного аппарата. В настоящее время врачам доступен отдельный класс лекарственных препаратов, инигибиторов ФНОa (иФНОa), эффективных в отношении таких многокомпонентных по своим проявлениям заболеваний, как псориатический артрит (ПсА). Представлен обзор результатов клинических исследований иФНОa голимумаба (ГЛМ), человеческого моноклонального антитела к ФНОa. ГЛМ оказывает положительное влияние на все проявления ПсА: артрит, псориатическое поражение кожи и ногтей, дактилит, энтезит, качество жизни.
ГЛМ отличается удобным способом введения – стандартная доза составляет 50 мг в виде подкожных инъекций 1 раз в месяц, а также низкой иммунногенностью молекулы. Полученные к настоящему времени данные свидетельствуют о том, что ГЛМ является эффективным лекарственным средством с профилем безопасности, соответствующим таковому всего класса ингибиторов ФНОα.
Об авторах
Татьяна Викторовна КоротаеваРоссия
115522, Москва, Каширское шоссе, 34А
Е. Ю. Логинова
Россия
115522, Москва, Каширское шоссе, 34А
Литература
1. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005 Oct;53(4):573.
2. Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum. 2009 Oct 15;61(10):1373–8. doi: 10.1002/art.24608.
3. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008 May;58(5):851–64. doi: 10.1016/j.jaad.2008.02.040.
4. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 Trial. Ann Rheum Dis. 2005 Aug;64(8):1150–7. Epub 2005 Jan 27.
5. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004 Jul;50(7):2264–72.
6. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-lind, randomized, placebo-controlled trial. Arthritis Rheum. 2005 Oct;52(10):3279–89.
7. Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis. 2013 Nov;72(11):1777–85. doi: 10.1136/annrheumdis-2012-202035. Epub 2012 Nov 17.
8. Cawson MR, Mitchell SA, Knight C, et al. Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. BMC Musculoskelet Disord. 2014 Jan 20;15:26. doi: 10.1186/1471-2474-15-26.
9. Au SC, Ramirez-Fort MK, Gottlieb AB. Analysis of trial data for infliximab and golimumab demonstrates that baseline CRP level predicts therapeutic response in patients with psoriatic arthritis. Arthritis Care Res (Hoboken). 2013 Dec 10. [Epub ahead of print]
10. Chimenti MS, Teoli M, Saraceno R, et al. Golimumab in patients affected by moderate to severe psoriatic arthritis: an open-label study in thirty-two patients previously treated with other biologics. Dermatology. 2013;227(4):305–10. doi: 10.1159/000354263. Epub 2013 Nov 19.
11. Helliwell PS, Kavanaugh A. Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab. Arthritis Care Res (Hoboken). 2014 May;66(5):749–56. doi: 10.1002/acr.22204.
12. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanism of action: a comprehensive review. Pharmacol Ther. 2008 Feb;117(2):244–79. Epub 2007 Oct 26.
13. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human, TNF alpha antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study. Arthritis Rheum. 2009 Apr;60(4):976–86. doi: 10.1002/art.24403.
14. Inman RD, Davis JC Jr, Heijde Dv, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis. Arthritis Rheum. 2008 Nov;58(11):3402–12. doi: 10.1002/art.23969.
15. Kay J, Fleischmann R, Keystone E, et al. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis. 2015 Mar;74(3):538–46. doi: 10.1136/annrheumdis-2013-204195. Epub 2013 Dec 16.
16. Xu Z, Vu T, Lee H, et al. Population pharmacokinetics of golimumab, an antitumor necrosis factor-α human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol. 2009 Sep;49(9):1056–70. doi: 10.1177/0091270009339192. Epub 2009 Jul 17.
17. Kavanaugh A, Mease P, Krueger GG, et al. Golimumab, a new human, TNF alpha antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study. Abstract presented at the 2009 European League Against Rheumatism (EULAR) Annual Congress. Jun 10Р13: Copenhagen.
18. Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial, the GO-REVEAL study). Ann Rheum Dis. 2014 Sep;73(9):1689–94. doi: 10.1136/annrheumdis-2013-204902. Epub 2014 Apr 19.
19. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006 Mar;54(3):692–701.
20. Chung E, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure. Circulation. 2003 Jul 1;107(25):3133–40. Epub 2003 Jun 9.
21. Kerbleski JF, Gottlieb AB. Dermatological complications and safety of anti-TNF treatments. Gut. 2009 Aug;58(8):1033–9. doi: 10.1136/gut.2008.163683.
22. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumor necrosis factor given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009 Jun;68(6):789–96. doi: 10.1136/ard.2008.099010. Epub 2008 Dec 9.
23. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology. 1999 Aug 11;53(3):457–65.
24. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 2001 Nov 27;57(10):1885–8.
25. Frankel AJ, Van Voorhees AS, Hsu S, et al. Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009 Dec;61(6):1044–55. doi: 10.1016/j.jaad.2009.03.044. Epub 2009 Oct 7.
Рецензия
Для цитирования:
Коротаева ТВ, Логинова ЕЮ. Голимумаб в лечении псориатического артрита: эффективность и безопасность. Современная ревматология. 2015;9(3):48-53. https://doi.org/10.14412/1996-7012-2015-3-48-53
For citation:
Korotaeva TV, Loginova EY. Golimumab in the treatment of psoriatic arthritis: efficacy and safety. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2015;9(3):48-53. https://doi.org/10.14412/1996-7012-2015-3-48-53
Послать статью по эл. почте 